Alzheimer's Disease

Source: www.ncbi.nlm.nih.gov --- 10 hours ago
21 new PubMed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: Alzheimer's Disease These PubMed results were generated on 2008/09/04 PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources. ...

Source: www.ncbi.nlm.nih.gov --- 8 hours ago
Related Articles In search of a treatment for Alzheimer's Disease and potential immunonosuppresive therapeutic interventions. Neuro Endocrinol Lett. 2008 Aug 2;29(4) Authors: Dhawan N, Saeed O, Shin J, Puangco J, Jandial R Alzheimer's Disease (AD) is a serious neurodegenerative Disease of aging. Recent projections of the dramatic increase in AD incidence worldwide by 2050 reveal its magnitude as a world-wide health crisis and underscore the urgent need to understand the etiology of AD in order to develop therapeutic interventions. A popular debate among scientists has traditionally pitted those in support of Beta amyloid protein as a causative factor ("Baptists") against others who implicate tau hyperphosphorylation ("Tauists"). Considering the significance of Beta amyloid protein and hyperphosphorlyated tau protein aggregates in AD pathology, this article delves into the nature of inflammation associated with these aggregates. Aspects of inflammation focus on microglia, resident immune cells of the CNS that are activated during AD inflammation and are known to play a significant role in pathogenesis. This article discusses the role of microglia, inflammation, and the immune response as a middle ground in the debate between the "Tauists" and the "Baptists" respective positions. It explores recent advances in immunotherapy and supports continued research in and use of immunosuppressive regimens as potential therapeutic interventions for ...

Source: www.ncbi.nlm.nih.gov --- 21 hours ago
13 new PubMed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: Alzheimer's Disease These PubMed results were generated on 2008/09/03 PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources. ...

Source: www.ncbi.nlm.nih.gov --- 1 day ago
Related Articles Statin-like drugs for the treatment of brain cholesterol loss in Alzheimer's Disease. Curr Drug Saf. 2007 Sep;2(3):173-6 Authors: Elisa B Aging is one of the most significant risk factors for neurological disorders including Alzheimer's Disease (late-onset AD and sporadic AD), the most common form of dementia. AD is characterized by progressive atrophy and loss of neurons resulting in cognitive deficits, confusion and dementia, culminating in childlike helplessness and death. One of the major pathological hallmarks of the Disease are amyloid plaques, composed primarly of insoluble fibrils of Abeta peptide: this molecule derives from the processing of the transmembrane amyloid precursor protein (APP) by different secretases and its production is a physiological event, but the anormal increase in Abeta levels appears to be toxic both in vitro and in vivo. Being APP cleavage a membrane event the involvement of lipids in alterations of this cleavage is assumable. Cholesterol is the most abundant lipid in cellular membranes and is an essential component of them, determining the fluidity and biophysical properties. In fact, genetic studies of the risk of AD have reported association with polymorphism in some cholesterol related genes like the allele epsilon4 of the apolipoprotein E, cholesterol 24-hydroxylase (CYP46A1), ATP-binding cassette transporter a1 (ABCA1) and the lipoprotein receptor-related protein (LRP). Moreover a ...

Source: www.ncbi.nlm.nih.gov --- 1 day ago
Related Articles Nasal Colivelin treatment ameliorates memory impairment related to Alzheimer's Disease. Neuropsychopharmacology. 2008 Jul;33(8):2020-32 Authors: Yamada M, Chiba T, Sasabe J, Terashita K, Aiso S, Matsuoka M Humanin (HN) and its derivatives, such as Colivelin (CLN), suppress neuronal death induced by insults related to Alzheimer's Disease (AD) by activating STAT3 in vitro. They also ameliorate functional memory impairment of mice induced by anticholinergic drugs or soluble toxic amyloid-beta (Abeta) in vivo when either is directly administered into the cerebral ventricle or intraperitoneally injected. However, the mechanism underlying the in vivo effect remains uncharacterized. In addition, from the standpoint of clinical application, drug delivery methods that are less invasive and specific to the central nervous system (CNS) should be developed. In this study, we show that intranasally (i.n.) administered CLN can be successfully transferred to CNS via the olfactory bulb. Using several behavioral tests, we have demonstrated that i.n. administered CLN ameliorates memory impairment of AD models in a dose-responsive manner. Attenuation of AD-related memory impairment by HN derivatives such as CLN appears to be correlated with an increase in STAT3 phosphorylation levels in the septohippocampal region, suggesting that anti-AD activities of HN derivatives may be mediated by activation of STAT3 in vivo as they are in vitro. We ...

Source: www.ncbi.nlm.nih.gov --- 1 day ago
Related Articles Apolipoprotein E mediates sulfatide depletion in animal models of Alzheimer's Disease. Neurobiol Aging. 2008 Aug 30; Authors: Cheng H, Zhou Y, Holtzman DM, Han X Herein, we tested a recently proposed working model of apolipoprotein E (apoE)-mediated sulfatide metabolism/trafficking/homeostasis with two well-characterized amyloid precursor protein (APP) transgenic (Tg) animal models of Alzheimer's Disease (AD) (i.e., APP(V717F) and APPsw) on a wild-type murine apoE background or after being bred onto an Apoe(-/-) background. As anticipated, lipidomics analysis demonstrated that the sulfatide levels in brain tissues were reduced beginning at approximately 6 months of age in APP(V717F) Tg, Apoe(+/+) mice and at 9 months of age in APPsw Tg, Apoe(+/+) mice relative to their respective non-APP Tg littermates. This reduction increased in both APP Tg mice as they aged. In contrast, sulfatide depletion did not occur in APP Tg, Apoe(-/-) animals relative to the Apoe(-/-) littermates. The lack of sulfatide depletion in APP Tg, Apoe(-/-) mice strongly supports the role of apoE in the deficient sulfatide content in APP Tg, Apoe(+/+) mice. Collectively, through different animal models of AD, this study provides evidence for an identified biochemical mechanism that may be responsible for the sulfatide depletion at the earliest stages of AD. PMID: 18762354 [PubMed - as supplied by publisher] ...

Source: jama.ama-assn.org --- 1 day ago
Context  Many observational studies have shown that physical activity reduces the risk of cognitive decline; however, evidence from randomized trials is lacking. Objective  To determine whether physical activity reduces the rate of cognitive decline among older adults at risk. Design and Setting  Randomized controlled trial of a 24-week physical activity intervention conducted between 2004 and 2007 in metropolitan Perth, Western Australia. Assessors of cognitive function were blinded to group membership. Participants  We recruited volunteers who reported memory problems but did not meet criteria for dementia. Three hundred eleven individuals aged 50 years or older were screened for eligibility, 89 were not eligible, and 52 refused to participate. A total of 170 participants were randomized and 138 participants completed the 18-month assessment. Intervention  Participants were randomly allocated to an education and usual care group or to a 24-week home-based program of physical activity. Main Outcome Measure  Change in Alzheimer Disease Assessment Scale–Cognitive Subscale (ADAS-Cog) scores (possible range, 0-70) over 18 months. Results  In an intent-to-treat analysis, participants in the intervention group improved 0.26 points (95% confidence interval, –0.89 to 0.54) and those in the usual care group deteriorated 1.04 points (95% confidence interval, 0.32 to 1.82) on the ADAS-Cog at the end of the intervention. The absolute differen ...

Source: voices.kansascity.com --- 1 day ago
By Lewis Diuguid, Kansas City Star Editorial Board member Baby boomers’ ability to contend with Alzheimer’s Disease will depend on lessons they pick up today about the scourge. Americans are living longer. Health officials have noted drops of more than 6 percent in stroke and chronic lower respiratory diseases such as emphysema and bronchitis. Heart Disease and diabetes deaths have fallen more than 5 percent. read more ...

Source: pharmalicensing.com --- 1 day ago
The measurement of GSK-3 in circulating white cells is a useful early diagnostic marker and potential therapy for Alzheimer's Disease. ...

Source: www.fwicki.com --- 23 hours ago
Main Category: Alzheimer's / Dementia Also Included In: Hypertension ; Seniors / Aging ; Clinical Trials / Drug Trials Article Date: 03 Sep 2008 - 2:00 PDT Treatment of hypertension has proven to reduce ... ...

Source: guidetoretirementliving.com --- 83 seconds ago
By Jessica Berman Washington 02 September 2008 � It is estimated the number of people with Alzheimer’s Disease will jump from 26 million today to 106 million worldwide by the year 2050. As researchers work to find a cure for the deadly brain Disease, experts are looking for ways to delay the onset of dementia caused by Alzheimer’s. VOA’s [...] ...

Source: www.topix.com --- 1 day ago
This chapter of CNS Drug Discoveries focuses on the Alzheimer's Disease market. By 2014, there will be considerable change in the Alzheimer's Disease market due to generic competition, better utilisation of ... ...

Source: www.naturalremediescures.com --- 14 hours ago
News release from The Alzheimer’s Research Trust -18 July 2008 British researchers have shown that drug vaccination can remove amyloid plaques from the brains of people with Alzheimer’s Disease, but unexpectedly found this did not slow down the Disease. The five-year study, funded by... ...

Source: www.ta.ecri.org --- 8 hours ago
Alzheimer's Disease (AD) is a progressive, degenerative, neurologic condition characterized by cognitive impairment and memory loss. AD is the most common cause of dementia among individuals 65 years of age and older. In patients with AD, brain cells located in the hippocampus (the brain's memory center) begin to die thereby interrupting the process of memory storage and recall. ...

Source: neckties.spaces.live.com --- 1 day ago
Alzheimer's Disease leads to a loss of mental ability severe enough to interfere with normal living and scars people's experience of their whole lives. The decrease in memory robs them of their past, the loss of ability to reason robs them of their present, and the inability to plan takes away what future the Disease leaves them. Read more . There is more to my life than neckties. Copyright © 2008 by Michael Segers, all rights reserved. ...

Source: www.afountainofyouth.org --- 1 day ago
Your Rx May Be Leading You To Alzheimer’s Disease ...

Source: www.moreover.com --- 9 hours ago
Pfizer announced a deal yesterday valued at as much as $725 million to develop and market an experimental treatment for Alzheimer's Disease. ...

Source: www.moreover.com --- 9 hours ago
Diabetics who take insulin plus a sulfonylurea diabetes pill have a lower risk of developing Alzheimer's Disease than diabetics who take insulin alone, researchers said. ...

Source: www.medicalnewstoday.com --- 20 hours ago
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL), a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, announced the successful completion of preclinical studies (in-vitro and in-vivo in mice) on ANAVEX 2-73, a novel sigma-1 receptor agonist for the treatment of Alzheimer's Disease. ...

Source: www.nanowerk.com --- 18 hours ago
The NAD (Nanoparticles for therapy and diagnosis of Alzheimer's Disease) Project is based on the use of nanoparticles for Alzheimer's diagnosis and therapy. The research, costing 14.6 million euros over 5 years, is financed by the European Union's 7th Framework Program and includes 19 European research centers. ...